A phase I trial of LXS196, a protein kinase C (PKC) inhibitor, for metastatic uveal melanoma. Piperno-Neumann S, Carlino MS, Boni V, Loirat D, et al. Br J Cancer 2023 Jan 9. doi: 10.1038/s41416-022-02133.

Read + Share

Amedeo Smart

Independent Medical Education

Piperno-Neumann S, Carlino MS, Boni V, Loirat D, et al. A phase I trial of LXS196, a protein kinase C (PKC) inhibitor, for metastatic uveal melanoma. Br J Cancer 2023 Jan 9. doi: 10.1038/s41416-022-02133.
PMID: 36624219